SYNTAX II研究:当代PCI策略治疗三支病变的1年临床结局
SYNTAX II研究为多中心、全纳入、开放标签、单臂研究,在22个欧洲中心对454例适宜PCI的三支病变患者采用当代PCI策略。1年MACCE为10.6%,优于SYNTAX-I等效PCI队列的17.4%(HR 0.58,95%CI 0.39-0.85,P=0.006),主要因心肌梗死和再次血运重建减少。
要点
- 当代PCI策略较SYNTAX-I等效PCI队列1年MACCE显著降低(10.6% vs 17.4%)。
- 心肌梗死(HR 0.27)和再次血运重建(HR 0.57)显著减少,全因死亡和卒中无差异。
- 明确支架血栓发生率显著降低(HR 0.26,95%CI 0.07-0.97,P=0.045)。
核心结论
- 1年时SYNTAX-II策略的临床结局优于原SYNTAX-I试验中可比患者的PCI结果。
- 需等待更长期随访,并有必要与当代CABG开展随机临床试验。
研究设计与样本
- 多中心、全纳入、开放标签、单臂研究,覆盖4个欧洲国家22个中心。
- 共筛查708例患者并经心脏团队讨论,454例被认为适合行PCI。
- 1年MACCE与SYNTAX-I试验中基于4年死亡等效性选择的预设PCI队列比较。
主要发现
- 1年MACCE在SYNTAX-II为10.6%,SYNTAX-I等效PCI队列为17.4%(HR 0.58,95%CI 0.39-0.85,P=0.006)。
- 心肌梗死HR 0.27(95%CI 0.11-0.70,P=0.007),再次血运重建HR 0.57(95%CI 0.37-0.9,P=0.015)。
- 全因死亡HR 0.69(95%CI 0.27-1.73,P=0.43)和卒中HR 0.69(95%CI 0.10-4.89,P=0.71)无显著差异。
- 明确支架血栓HR 0.26(95%CI 0.07-0.97,P=0.045),SYNTAX-II显著更低。
关键数值与推荐
- SYNTAX-II策略包括:基于SYNTAX Score II的心脏团队决策、冠脉生理学指导血运重建、薄 strut 生物可吸收聚合物药物洗脱支架、IVUS指导支架植入、当代CTO开通技术及指南导向药物治疗。
- MACCE定义为全因死亡、脑血管事件、任何心肌梗死和任何血运重建的复合终点。
临床怎么用
- 对适宜的三支病变患者,采用包含SYNTAX Score II决策、生理学评估、IVUS指导和当代DES的综合PCI策略可改善1年临床结局。
- 该策略主要降低心肌梗死、再次血运重建和明确支架血栓风险,全因死亡和卒中未见显著差异。
局限性
- 单臂研究设计,主要比较对象为历史队列而非同期随机对照。
- 随访时间仅1年,长期结局尚待观察。
- 与当代CABG的比较仅为探索性分析,需随机临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate if recent technical and procedural developments in percutaneous coronary intervention (PCI) significantly influence outcomes in appropriately selected patients with three-vessel (3VD) coronary artery disease. METHODS AND RESULTS: The SYNTAX II study is a multicenter, all-comers, open-label, single arm study that investigated the impact of a contemporary PCI strategy on clinical outcomes in patients with 3VD in 22 centres from four European countries. The SYNTAX-II strategy includes: heart team decision-making utilizing the SYNTAX Score II (a clinical tool combining anatomical and clinical factors), coronary physiology guided revascularisation, implantation of thin strut bioresorbable-polymer drug-eluting stents, intravascular ultrasound (IVUS) guided stent implantation, contemporary chronic total occlusion revascularisation techniques and guideline-directed medical therapy. The rate of major adverse cardiac and cerebrovascular events (MACCE [composite of all-cause death, cerebrovascular event, any myocardial infarction and any revascularisation]) at one year was compared to a predefined PCI cohort from the original SYNTAX-I trial selected on the basis of equipoise 4-year mortality between CABG and PCI. As an exploratory endpoint, comparisons were made with the historical CABG cohort of the original SYNTAX-I trial. Overall 708 patients were screened and discussed within the heart team; 454 patients were deemed appropriate to undergo PCI. At one year, the SYNTAX-II strategy was superior to the equipoise-derived SYNTAX-I PCI cohort (MACCE SYNTAX-II 10.6% vs. SYNTAX-I 17.4%; HR 0.58, 95% CI 0.39-0.85, P = 0.006). This difference was driven by a significant reduction in the incidence of MI (HR 0.27, 95% CI 0.11-0.70, P = 0.007) and revascularisation (HR 0.57, 95% CI 0.37-0.9, P = 0.015). Rates of all-cause death (HR 0.69, 95% CI 0.27-1.73, P = 0.43) and stroke (HR 0.69, 95% CI 0.10-4.89, P = 0.71) were similar. The rate of definite stent thrombosis was significantly lower in SYNTAX-II (HR 0.26, 95% CI 0.07-0.97, P = 0.045). CONCLUSION: At one year, clinical outcomes with the SYNTAX-II strategy were associated with improved clinical results compared to the PCI performed in comparable patients from the original SYNTAX-I trial. Longer term follow-up is awaited and a randomized clinical trial with contemporary CABG is warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT02015832.
引用
- Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017. PMID: 29020367. doi:10.1093/eurheartj/ehx512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。